Abstract
Exosomes are small membranous vesicles that contain proteins, lipids, genetic material, and metabolites with abundant information from parental cells. Exosomes carry and deliver bioactive contents that can reprogram the functions of recipient cells and modulate the tumor microenvironment to induce pathological events through cell-to-cell communication and signal transduction. Tumor-derived exosomes (TDEs) in head and neck squamous cell carcinoma (HNSCC) are involved in most aspects of cancer initiation, invasion, progression, immunoregulation, therapeutic applications, and treatment resistance. In addition, HNSCC-derived exosomes can be used to obtain information on diagnostic and therapeutic biomarkers in circulating blood and saliva. Currently, the biology, mechanisms, and applications of TDEs in HNSCC are still unclear, and further research is required. In this review, we discuss various aspects of exosome biology, including exosomal components, exosomal biomarkers, and molecular mechanisms involved in immunoregulation, cancer metastasis, and therapy resistance. We also describe recent applications to update our understanding of exosomes in HNSCC.
Introduction
Head and neck cancer (HNC) is one of the most widespread malignancies worldwide. Although continual progress has been made in the treatment of HNC, the 5-year overall survival rate of advanced HNC remains low at approximately 50% (1, 2). HNC frequently develops from mucosal surfaces of the mouth, including the oral cavity (tongue, lip, buccal, gingiva, and palate), oropharynx, larynx, and perioral skin carcinoma (3). More than 90% of HNCs are head and neck squamous cell carcinoma (HNSCC). The exact etiology of HNSCC remains unclear; however, tobacco and alcohol consumption are major risk factors for HNSCC, as demonstrated in epidemiological studies. Mucosal human papilloma virus (HPV) is also related to a subset of HNSCCs; ~25.9% of HNSCCs are HPV positive, whereas the prevalence of HPV in oropharyngeal squamous cell carcinoma (SCC) is 34.1%, which is higher than that in oral SCC (4).
Exosomes, which were first discovered in 1983, are 30–150 nm mature double membrane multivesicular bodies (MVBs) originating from the endosomal pathway (5). Exosomes exist in the extracellular space and in liquids, such as blood, urine, and saliva (6). Exosomes are associated with many physiologic aspects of the disease via intercellular communication and signal transduction, indicating that exosomes have potential clinical applications as biomarkers and therapeutic targets. Tumor-derived exosomes (TDEs) contain a cytomembrane, proteins, nucleic acids, lipids, and other substances from parental tumor cells (7). Moreover, exosomes are known to be involved in nearly all stages of cancer (8–11). Growing evidence has demonstrated that TDEs participate in the development, progression, and treatment of cancer by mediating intercellular communication and signal transduction (12, 13). The bioactive components of HNSCC-derived exosomes, such as microRNAs, transcription factors, and oncogenic proteins, play key roles in mediating tumorigenesis, tumor microenvironment reprogramming, immune tolerance, promoting metastasis, and therapy resistance. For example, intracellular annexin 1 (ANXA1) regulates epidermal growth factor receptor (EGFR) activity and alter the release of EGFR-containing TDEs in HNCs (14). Exosomes produced by hypoxic oral SCC cells deliver viral miR-21 to normoxic cells, inducing the epithelial-mesenchymal transition (EMT) to promote cell migration and invasion (15). Another study showed that exosomal nuclear factor-κB-activating kinase-associated protein 1 (NAP1) derived from oral cancer promotes the cytotoxicity of natural killer (NK) cells via activation of the interferon regulatory factor (IRF-3) signaling pathway in recipient cells (16). In addition, miR-34a-5p in cancer-associated fibroblast (CAF)-derived exosomes in oral SCC stimulates the proliferation and metastasis of oral cancer cells through the AKT/glycogen synthease kinase-3β/β-catenin/Snail signaling cascade (17). A recent study demonstrated that thrombospondin 1 derived from oral SCC exosomes is also involved in the polarization of macrophages to M1-like tumor-associated macrophages and promotes the invasion of cancer cells (18). HNSCC-derived exosomes containing EphrinB1 may manipulate the tumor microenvironment through induction of tumor innervation (19). Additionally, Sento demonstrated that oral SCC-derived exosomes promote tumor growth by activating the phosphatidylinositol 3-kiase (PI3K)/AKT, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase-1/signal transducer and activator of transcription (STAT) 2 pathways (20). Emerging evidence has supported the vital role of TDEs in the development, progression, and treatment of HNSCC.
In this review, we summarize many aspects of exosome biology and functions in HNSCC.
Biogenesis, Features, and Components of Exosomes
Inward Budding and MVB Formation
Different types of vesicles, including extracellular vesicles (EVs), MVBs, and exosomes, have been described and often labeled interchangeably in many previous studies. Although these different types of vesicles share overlapping features, they have distinct morphologies, properties, biogenesis mechanisms, and functional roles. Plasma membrane components and enclosing cytosolic components are incorporated into the invaginating membrane, resulting in the formation of early endosomes (21). Exosomes typically originate from inward budding from the membrane and are then released into the extracellular space via activation of Ca2+-dependent or Rab-GTPases (22). Briefly, exosomes are generated from early endosomes, mature into MVBs, and are then secreted into the extracellular space upon fusion with the plasma membrane. First, exosomes start as early endosomes, which are formed by endocytosis of the plasma membrane. The biogenesis of exosomes and sorting of functional cargo is precisely regulated by certain mechanisms involving multiple factors. The most commonly described pathway for exosomes biogenesis is the endosomal sorting complex required for transport (ESCRT) machinery. Four types of ESCRTs (ESCRT-0–III) are involved in regulating MVB formation, vesicle budding, and protein cargo sorting (23). The ESCRT mechanism is initiated and sequestrated by ubiquitinated proteins to domains of the endosomal membrane via ubiquitin binding subunits of ESCRT-0 in the endosomal membrane, then interacting with the ESCRT-I and ESCRT-II complexes inducing membrane deformation into buds. Finally, the ESCRT-III complex separates from the MVBs membrane (23–25). However, the machinery that drives the load of protein cargo into ESCRT-dependent exosomes is still unclear.
Cells also utilize ESCRT-independent pathways, involving insphingosine-1-phosphate, ceramide, tetraspanin-enriched microdomains, and sphingomyelinase, for exosome production and release (26–28). These ESCRT-independent mechanisms may participate in promoting domain-induced budding, sorting of bioactive molecules into exosomes, segregation of cargo within the endosomal membrane, and exosome formation.
The ESCRT-dependent and -independent mechanisms of exosome release are based on the cell origin. In addition, membrane proteins of lysosomes and late endosomes may be important for the biogenesis and secretion of exosomes (29).
Regulated Secretion and Intercellular Interactions
Exosome secretion is involved in various signaling pathways. For example, the key regulatory role of RAB family proteins in trafficking intracellular exosomes was demonstrated by Colombo et al. (30). Another report showed that the Wnt pathway is particularly important for the dysregulation of exosome release in cancer cells (31). Additionally, the secretion of exosomes is mediated through exocytosis-associated molecular motors and cytoskeletal proteins (32). Spontaneous secretion of exosomes usually occurs at the steady state; however, some conditions are known to stimulate exosomes. Indeed, cell intrinsic signals are known to enhance the release of high levels of TDEs from cancer cells via activation of oncogenic signaling pathways or regulation of membrane fusion machinery (33). In addition, evidence suggests that microenvironmental conditions enhance exosome release from cancer cells (15, 34). Exosomes are then released into the extracellular environment through exocytosis or degraded by fusing with lysosomes. As previously described, Rab GTPases are essential regulators of exosome secretion. Furthermore, several studies have shown that soluble N-ethylmaleimide-sensitive component attachment protein receptor complexes, which are involved in membrane fusion machinery, may affect the secretion of exosomes (35–37).
Ultimately, exosomes are internalized by recipient cells through receptor-mediated endocytosis, pinocytosis, phagocytosis, or fusion with the cell membrane, resulting in delivery of molecular and genetic components into the recipient cells (30). Exosomes target recipient cells after secretion into the extracellular space and then induce changes in downstream signaling pathways. The specificity of target recipient cells is dependent on the type of ligand/receptor pairs present on exosomes and recipient cells; and a study provides further insight that glycans are key players in the process of exosomes uptake (38). A schematic representation of exosome biogenesis and secretion pathways is shown in Figure 1.
Figure 1
Features and Components of Exosomes
Typical exosomes exhibit a particular biconcave or cup-like shape and are observed as spheroids under transmission electron microscopy (39). Exosome contents are rich in nucleic acids, cytosolic/endosome proteins, and cytoskeleton components, which have unique biological activities (40). The components of TDEs are distinct from those of exosomes released from healthy cells. TDEs deliver functional cargo, including oncogenes and oncogenic proteins that can exert biological activities. The functional cargoes, such as protein cargo, RNA cargo, and DNA cargo, of TDEs in the tumor microenvironment have an important role in promoting cancer progression and metastasis (Figure 1) (33). Protein cargoes, including different oncoproteins, immunomodulatory molecules, and growth factors, act as mediators of tumorigenesis. TDEs also contain abundant nucleic acids, such as microRNAs (miRNAs), mRNA, long noncoding RNAs, and DNAs, which deliver genetic information (41–43).
Many researchers have analyzed the functions of miRNAs in exosomes, and various specific miRNA cargoes and extracellular components have been detected in exosomes. These observations highlight the specificity of exosomal miRNAs, distinct miRNA signatures of exosomes, and various functions of exosomal miRNAs. A series of experiments have analyzed the function of the miRNAs in exosomes since their initial description (44). It has been reported that there was a selection of specific miRNA cargoes and extracellular exports in exosomes (30). These observations highlight the specificity of exosomal miRNAs, distinct miRNA signatures of exosomes, and various functions of exosomal miRNAs. Exosomal miRNAs are associated with a variety of pathological activities, including tumorigenesis, invasion, progression, angiogenesis, metastasis, and chemoresistance. However, not all exosomal miRNAs are implicated in tumor-supportive mechanisms. miRNAs of exosomes are highly functional, with roles in intercellular communication and tumor microenvironment regulation, indicating that exosomal miRNAs play important roles in diagnostic and therapeutic applications.
In addition, exosomes contain ceramides, lipids, sphingolipids, cholesterol, and glycerophospholipids. Because exosomes originate from the fusion of endocytic compartments with the plasma membrane, the protein, lipid, and double lipid layer compositions can be used to identify exosomes. The most commonly identified markers are ALIX and tetraspanins, such as CD9, CD63, CD81, and CD82 (23).
Functions of Exosomes in HNSCC
Exosomes have been identified as bioactive and informative nano-sized MVBs that influence many aspects of the development and progression of HNSCC. Here, we discuss recent findings of the mechanisms through which HNSCC-derived exosomes modulate the immune response, tumor microenvironment, cell-to-cell communication, and tumor invasion. We also describe exosomes as potential biomarkers and discuss their applications in cancer therapy and therapy resistance.
Exosomes as Potential Biomarkers
In the clinical setting, some relevant biomarkers have been shown to influence treatments for patients with HNSCC. Several reports have shown that liquid biopsies, including biopsies of circulating tumor DNA, circulating tumor cells, and exosomal miRNAs, can have potential clinical applications in HNC (45). Moreover, HPV status is a prognostic factor in HNSCC; patients with HPV positivity have better responsiveness to chemotherapy and radiotherapy and are more susceptible to immune surveillance. In addition, miRNAs are independent prognostic markers for patients with HPV-negative HNSCC (46), and EGFR overexpression is associated with poorer prognosis and outcomes in HNSCC (47). However, further studies are needed to establish biomarkers for staging HNSCC and facilitating therapeutic decision-making.
Exosomes modulate various pathological activities to promote cancer cell growth, invasion, and distant metastasis. TDEs also carry valuable genomic and proteomic information and can provide information regarding alterations in genomic and proteomic profiles of exosomes from patients with cancer in response to anticancer therapies (48). Such proteomic and genetic components are well-protected within the lipid bilayer and can be preserved without significant loss of functional profiling. Therefore, exosomes may serve as promising markers for monitoring cancer progression and therapeutic responses (49).
TDEs can be obtained from blood or saliva of patients with HNSCC, indicating that TDEs may represent a real-time, non-invasive, clinically relevant biomarker of cancer progression, and treatment responses (45, 50–53). For example, the number of exosomes in the plasma has been shown to be a prognosis indicator for HNSCC. Gimzewski reported that elevated exosome numbers, exosome sizes, and interexosomes were detected in the saliva of patients with oral cancer (54). In addition, patients with HNSCC with advanced-stage disease and shorter overall survival usually exhibit elevated levels of exosomes in the plasma, indicating that plasma exosomes in HNSCC may have applications in monitoring tumor progression (52, 54). One previous study demonstrated that TDE signatures could serve as candidate biomarkers for early cancer diagnosis, monitoring, and surveillance in HPV-16-associated oropharyngeal (55). Moreover, a non-invasive method involving Fourier-transform infrared spectroscopy of salivary exosomes was shown to have high sensitivity and specificity in the diagnosis of oral cancer (56).
Non-coding RNAs from plasma exosomes have been extensively studied as potential biomarkers in HNSCC because they are derived from whole tumor cells and may therefore represent whole cellular RNAs (57, 58). Several studies have reported that cancer cells can selectively pack selected miRNAs into exosomes, and these selective exosomal miRNAs then act as tumor suppressors or oncogenes in HNSCC (59–61). Additionally, a hypoxic microenvironment can stimulate oral SCC to generate miR-21-rich exosomes, which are associated with lymph node metastasis (15). Serum exosomal miR-21 and homeobox transcript antisense RNA (HOTAIR) are also significantly associated with the clinical characteristics of laryngeal SCC (59). In a previous study, elevated CAF-derived exosomal miR-196a levels were shown to be correlated with cisplatin resistance in HNSCC through targeting cyclin-dependent kinase (CDK) N1B and inhibitor of growth family member 5 (ING5), indicating that this miRNA may serve as a promising predictor of cisplatin resistance and poor survival in HNSCC (60). A study by Zhou and colleagues revealed that there were significant differences in expression between exosomal miRNAs and cellular miRNAs in laryngeal SCC (61). Furthermore, oral cancer-derived salivary exosomal miR-512-3p and miR-412-3p may serve as potential biomarkers (62). In another example, Inazawa and colleagues found that exosomal miR-1246 induces cell motility and invasion through directly targeting differentially expressed in normal vs. neoplastic/MAPK-activating death domain-containing 2D in oral SCC (63). Collectively, these results suggested that exosomal miRNAs could serve as excellent diagnostic and prognostic biomarkers.
Analysis of exosomal proteins is a novel tool for developing exosomes as potential biomarkers for HNSCC. More than 80% of HNSCCs exhibit overexpression of EGFR in the membrane, and hyperactivity EGFR plays an important role in tumorigenesis development and drug-resistance mechanisms by activating various signaling pathways, including the PI3K/AKT, RAS/MEK/ERK, and Janus kinase (JAK)/STAT pathways, in HNSCC. A recent study showed that EGFR can be secreted from cells via the transport of exosomes and that these EGFR-containing exosomes have the ability to regulate autocrine VEGF production in endothelial cells (64). Exosomal EGFR mediates metastasis and tumor immunity in lung cancer (65). ANXA1, a tumor suppressor in HNSCC, regulates EGFR activity and exosomal phospho-EGFR release, revealing that exosomal EGFR and phospho-EGFR may be prognostic biomarkers in HNSCC (14). Additionally, the levels of exosomal EGFR and phospho-EGFR are reduced after cetuximab treatment, indicating that exosomes can serve as biomarkers to monitor cetuximab treatment (66).
Analysis of exosome protein profiles showed that the characteristics and functions of exosomes from HPV-positive/-negative HNC differed significantly. HPV-positive exosomes had low p53 levels and did not contain cyclin D1, but did harbor p16, E6/E7, and the T-cell inhibitory protein PTPN11 (67). A recent study revealed that proteome analysis of salivary extracellular vesicles may yield prognostic biomarkers for oral SCC (68).
The microenvironment of HNSCC is highly immunosuppressive, and the programmed cell death (PD)-1/PD-ligand 1 (PD-L1) pathway plays an important role in HNSCC. High levels of PD-L1 are associated with poor outcomes in various types of cancer, including HNSCC. PD-1 checkpoint inhibitors were found to be safe and effective in platinum-refractory recurrent or metastatic HNSCC (69, 70). Furthermore, a study by Whiteside and colleagues indicated that PD-L1+ exosomes in the plasma were related to immune suppression and disease progression. Additionally, blocking PD-L1+ exosome signaling to PD-1+ T cells attenuated immune suppression in patients with HNSCC (71). In another study, Ferris reported that JAK2/STAT1 signaling was involved in EGFR-mediated immune evasion in HNSCC and that therapies targeting this signaling pathway may be beneficial for blocking PD-L1 upregulation in HNSCC (72). Moreover, elevated heat-shock protein 90 levels in TDEs have been reported to serve as potential biomarkers for clinical stage and prognosis in patients with oral cancer (73). A recent study showed that plasma-derived exosomes were associated with disease progression of HNSCC after separation into CD3+ and CD3− fractions (74). Furthermore, HNSCC-derived exosomes have been shown to exhibit synergistic interactions with invadopodia, indicating that exosomes play key roles in promoting cancer invasion (35). TDEs inducing transcriptome reprogramming can cause cancer-associated pathologies in HNSCC, including angiogenesis, immunoregulation, and metastasis; these functional differences in HNSCC may serve as candidate markers (75).
A growing body of evidence has shown that the characteristics of TDEs and exosomal components (e.g., exosomal miRNAs, exosomal proteins) may serve as potential noninvasive biomarkers for the detection, monitoring, and treatment of HNSCC (Figure 2). However, methods for TDE isolation and separation are complicated and time-consuming, and additional studies of TDEs as non-invasive biomarkers are needed.
Figure 2
Roles in Regulating the Tumor Microenvironment
Immune Cells
The tumor microenvironment is formed by stromal cells and is associated with malignant progression (76). Moreover, TDEs play important roles in regulating the tumor microenvironment of HNC (77). The immunological activities of exosomes are related to many aspects of immune regulation, including antigen presentation, immune activation, immune surveillance, and immune suppression. Tumor-infiltrating myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T cells (Tregs) are known mediators of the immunosuppressive microenvironment and limit the efficacy of immune therapy in HNC (78). Exosomes that contain immunosuppressive molecules can facilitate immunosuppression in cancer, which helps cancer cells escape from immune responses, thereby promoting tumorigenesis (79, 80). Additionally, exosome-associated bioactive proteins and RNAs have been shown to regulate the immune system (81, 82). Exosomes may mediate immune suppression through directly/indirectly inhibiting the functions of T cells and NK cells and then altering the number or activity of immune suppressor cells, including MDSCs, Tregs, and HLA-DR cells (83). Exosomes are also involved in different soluble factors such as check-point receptor ligands (PD-L1), inhibitory cytokines (IL-10 and TGF-β1), death receptor ligands (FasL), ectoenzymes, and prostaglandin E2 responsible for antitumor immunity in the tumor microenvironment (84, 85). In lymphocytes and NK cells, exosomes are associated with disease stage and activity in patients with HNC, suggesting that plasma exosomes may be related to HNC progression (86). In cancer, exosome signaling may affect the immune system by inhibiting the maturity of antigen-presenting cells and TDEs that carry and transfer tumor antigens to antigen-presenting cells, thereby inducing T cell- or NK cell-dependent immune responses (87). In a similar study, TDEs containing FasL and tumor necrosis factor α were found to induce T-cell apoptosis, thereby establishing an immunosuppressive tumor microenvironment to support tumor progression (88). TDEs derived from multiple HNCC cell lines induce a suppressive phenotype in CD8+ T cells through galectin-1, indicating that tumor-derived immunosuppressive exosomes may be potential therapeutic targets for preventing T-cell dysfunction and enhancing antitumor immune responses (89). As previously mentioned, the levels of oral SCC-derived FasL+ microvesicles are correlated with tumor burden, and the FasL+ microvesicles are involved in mediating apoptosis in activated T lymphocytes via receptor and mitochondrial pathways (51). A recent study showed that CD4+CD39+ Tregs produce adenosine by exposure to CD39+CD73+ exosomes from plasma in patients with HNSCC, thereby supporting tumor immune escape (90). Additionally, a recent study showed that oxygen pressure regulates the tumor microenvironment by altering exosomal miRNAs, which subsequently regulate the miR-21/phosphatase and tensin homolog (PTEN)/PD-L1 axis (91).
HPV-Positive and -Negative Exosomes
The molecular and functional profiles of exosomes from HPV-positive and -negative HNSCC are different. An early study demonstrated that HNSCC-derived exosomes have different effects on the immune system in HPV-positive and -negative HNSCC. However, there are no differences in suppressive CD4+ and CD8+ T cells between HPV-positive and -negative exosomes, although the responses of human monocyte-derived dendritic cells (DCs) and mature DCs to exosomes are different. HPV-positive exosomes promote DC maturation, whereas HPV-negative exosomes suppress DC maturation. HPV-negative exosomes suppress the expression of antigen processing machinery, whereas HPV-positive exosomes do not (67). HPV-positive exosomes that promote DC maturation may also stimulate antitumor immune responses, thereby improving clinical outcomes in patients with HPV-positive HNSCC (67). HPV has been shown to utilize host exosomes for cell-cell communication and to induce EGFR expression and AKT signaling in recipient cells. One study found that exosomal NAP1 derived from oral cancer cells can promote the activation of NK cells by increasing the expression and phosphorylation of IRF-3 (92).
Fibroblasts
CAFs are particularly important for regulating tumor progression. Mesenchymal stem cells reprogrammed by TDEs mediate pro-angiogenic activity and convert stromal cells into CAFs; these cells are a major component of the tumor microenvironment and play key roles in promoting tumor progression (93). HNC-derived CAFs are innately resistant to cisplatin. Indeed, a study by Zhang showed that exosomal miR-196a derived from HNC causes cisplatin resistance by targeting CDKN1B and ING5, highlighting the roles of CAF-derived exosomal miR-196a in promoting cell proliferation and inhibiting cell apoptosis in the HNC microenvironment (60). Moreover, high expression of microfibril associated protein 5 in CAF-derived exosomes may contribute to the proliferation and metastasis of oral SCC via activation of the MAPK and AKT signaling pathways (94). Additionally, TDEs have been shown to deliver caveolin-1 to the tumor microenvironment to mediate the EMT and CAFs in tongue SCC (95). In a similar study, CAF-derived exosomal miR-34a-5p was found to be associated with oral cancer cell proliferation and metastasis in oral SCC (17). Thus, TDEs are emerging as potent mediators of the tumor microenvironment in HNSCC (Figure 3).
Figure 3
Roles of TDEs in Regulating Cancer Progression and Metastasis
Many studies have evaluated the roles of TDEs in cancer initiation and progression. Numerous molecules in TDEs have been implicated in the initiation and progression of cancer cells or the tumor microenvironment (96). Indeed, TDEs can transform epithelial cells into cancerous cells, thereby initiating tumorigenesis. Studies have shown that TDEs reprogram the functions of recipient cells and facilitate premetastatic niche transformation to promote metastasis through cell-cell communication or autocrine signals. Additionally, TDEs facilitate tumor progression by delivery of factors necessary for sustaining tumor growth via utilizing autocrine or juxtacrine signaling (97). Furthermore, many studies have shown that RNA from TDEs can promote metastasis (57). The shuttling of miRNA molecules may cause tumorigenesis, tumor progression, and mRNA entry into recipient cells, resulting in protein translation and metastasis (44). The EMT has been implicated in cancer cell progression and metastasis, and TDEs deliver functional complexes by membrane fusion with recipient cells and binding of the recipient cell membrane receptors to promote the EMT (98).
Exosomes derived from hypoxic oral SCC cells promote cell migration and invasion by delivering miR-21 to normoxic cells in HNSCC (15). Nakashima conducted a study indicating that miR-200c-3p had invasive capacity in the human oral SCC microenvironment (99). Moreover, CAFs contribute to the proliferation and metastasis of oral cancer cells via exosome-mediated paracrine miR-34a-5p signaling (17). Several studies have reported the heterogeneity of transforming growth factor (TGF) β signaling in oral cavity SCC. TGFβ expressed on the surface of TDEs can differentiate fibroblasts into myofibroblasts, thereby promoting tumor progression and metastasis in oral cavity SCC (100). Additionally, exosomes target different organs via variations in integrin molecules expressed on the surface. Released exosomes can be delivered to distant organs to promote oncogenic activity by constructing a suitable premetastatic tumor microenvironment for tumor migration. Thus, TDEs contribute to the development of this premetastatic niche and induce metastatic potential in recipient cells. A recent study showed that exosomes can transport EGFR to the liver to remodel the liver microenvironment (101). TDEs can transfer oncogenic EGFR to endothelial cells, triggering upregulation of vascular endothelial growth factor (VEGF) and autocrine VEGF in endothelial cells exposed to cancer cell-related MVs (64). Moreover, oral cancer cell-derived MVs promote endothelial cell angiogenesis through the Shh/RhoA signaling pathway (102). Additional experiments have demonstrated that exosomal miR-150 promotes tumorigenesis by upregulating VEGF, and another study showed that HNSCC-derived exosomes stimulate angiogenesis in vitro and in vivo through functional reprogramming of endothelial cells (103). These studies suggest that exosomal miRNA could affect the biology of endothelial cells; then the exosomal miRNA induces angiogenesis in HNC through different regulation pathways.
TDEs modulate the immune response in tumor microenvironment interactions implicated in cancer progression. Oral SCC-derived exosomes induced M1-like TAMs polarized and promoted tumor metastasis (18). And tumor released exosomes containing EphrinB1 potentiate induce axonogenesis will promote tumor innervation in HNSCC (19). And the delivery of miRNA-21-abundant exosomes promote EMT-mediated M2-like polarization of TAMs may promote tumor progression of HNSCC (104). Another study demonstrated that exosomes derived from irradiated HNSCC cells can modify cancer cell movement and promote migration of recipient cells through AKT-signaling (105). In an additional series of experiments, exosomes were recruited to the plasma membrane of invadopodia, and knockdown of Rab27a decreased exosome secretion and extracellular matrix digestion associated with maturing invadopodia (35). The mechanisms through which TDEs regulate cancer progression and metastasis are illustrated in Figure 3.
Therapeutic Application
Exosomes are cell-derived nanoparticles that have unique properties, such as low immunogenicity, strong ability to cross physiological barriers, good biodistribution and bioavailability, and reduced immunogenicity. Thus, TDEs may have important roles as potential vehicles for anticancer drugs. In addition, exosomes can be remodeled through their parental cells or supplemented with desired biological activity (106). Exosomes have been designed as promising therapeutic agents in the treatment of various cancers (107–109). Because patients with metastatic HNSCC have a poor prognosis and do not typically respond well to traditional therapies, efficient targeted delivery of conventional chemotherapeutic drugs may be facilitated by innovative approaches to engineering drug delivery systems, such as exosomes.
Drug carrier exosomes have been isolated from various types of cells, including HEK-293 cells, immature DCs, macrophages, and cancer cells. Different therapeutic agents, including proteins, small interfering RNAs (siRNAs), miRNAs, and targeted drugs, can be incorporated into exosomes via electroporation, chemical-based transfection, modification of parental cells, or direct incubation, thereby increasing bioactivity and achieving targeted delivery in patients. The James Graham Brown Cancer Center initiated a phase I clinical trial to test the therapeutic effects of plant exosomes in HNC (NCT01668849). In various types of cancer, exosomes have been shown to shuttle miRNAs and soluble proteins as therapeutic molecules into recipient cells and tissues (107, 110). A hypoxic microenvironment promotes the generation of miR-21-rich exosomes by oral SCC in a hypoxia-inducible factor (HIF)-1a- and HIF-2a-dependent manner, and these miR-21-rich exosomes then mediate migration and invasion behaviors. Restoration of miR-21 expression in HIF-1a- and HIF-2a-depleted exosomes rescues oral SCC migration and invasion (15). Moreover, hypoxic TDEs mediate MDSC function through the miR-21/PTEN/PD-L1 axis in oral SCC (91). These findings indicate the therapeutic value of exosome inhibition for oral SCC treatment.
Anti-EGFR nanobodies anchored on extracellular vesicles via glycosyl phosphatidylinositol may improve the targeting ability of extracellular vesicles, highlighting the potential applications of these extracellular vesicles as a drug delivery system and new tool in EGFR-expressing tumor cells (111). The blood-brain barrier restricts drugs from entering into the brain, which can reduce the therapeutic effects of brain cancer treatments. Brain endothelial cell-derived exosomes can deliver anticancer drugs across the blood-brain barrier for the treatment of brain cancer. Additionally, exosome-based drug carriers can mediate permeability across the blood-brain barrier, enabling the drug to target cancer cells (112).
The main rational approaches for inhibiting exosome-mediated tumor-promoting potential have focused on blocking exosome release and suppressing the communication of tumor cells with recipient cells. TDEs are known to be abundantly secreted from cancer cells, making them potential targets for anticancer therapy. Direct targeting of the exosome release process has also been studied for the treatment of cancer. Exosome-delivered transient receptor potential polycystic 2 (TRPP2) siRNA markedly suppresses TRPP2 expression and inhibits the EMT, suggesting that exosome-TRPP2 siRNA may be an effective RNA-based gene therapy in the treatment of HNC (113). Invadopodia also enhance exosome secretion; accordingly, silencing the expression of invadopodia may suppress TDE biogenesis and release (114). Another potential strategy for exosomal dysregulation is the inhibition of exosome uptake. Treatment with heparin blocks the uptake of exosomes by oral SCC cells, thereby attenuating exosome-induced cancer progression to inhibit the growth and progression of oral SCC cells (20). However, the use of these reagents for eliminating exosomes is currently limited to research use only because these reagents may also induce off-target effects. Further studies are needed to explore the translational implications of exosome-targeted reagents.
Owing to the potential presence of TDEs and the unique biomarkers associated with these vesicles, TDEs may also have applications as vaccine immunotherapies (115). Antigen-presenting exosomes from B lymphocytes and DCs containing MHCI/II complexes could stimulate CD4+ and CD8+ T cells as therapeutic HPV vaccines (116). Additionally, HPV oncogenes play vital roles in HPV-induced carcinogenesis, and silencing of endogenous HPV E6/E7 expression affects both the contents and levels of MVs released from HPV-positive cancer cells (117). These findings indicate that inhibition of endogenous HPV E6/E7 expression may have therapeutic applications. HPV vaccines based on endogenously engineered exosomes for HNC have been evaluated in several phase I clinical trials (118). However, additional studies are required to determine the feasibility and safety of TDEs as cancer vaccines. One of the major challenges in developing this approach is establishing scalable, reproducible methods for exosome production. MSCs may have uses in exosome production at a clinically applicable scale owing to their ability of produce large amounts of exosomes.
Collectively, these studies suggest that exosome-based strategies may have many benefits over conventional drug regimens; however, there are some limitations and challenges to the use of exosomes. First, because TDEs contain genetic components from cancer cells, cancer cells may not be suitable parental cells for exosome targeting in clinical applications. Additionally, efficient loading of exosomes without significant alterations to the structure and content of exosomal membranes may be difficult. Overall, these reports indicate that exosomes may function as exceptional gene delivery vectors that are safe, efficient, organ-/cell-specific, and nonimmunogenic. Nevertheless, significant efforts are required to before clinical applications are feasible.
Anti-Cancer Therapy Resistance
Current therapy options for HNSCC include surgery, radiotherapy, chemotherapy, anti-EGFR-antibody treatment, and immunotherapy (119). However, drug resistance remains a major obstacle for achieving successful curative treatment of cancer. Drug resistance includes endogenous drug resistance, innate drug resistance, and acquired drug resistance. Acquired drug resistance is a process through which cancer cells exposed to chemotherapy, radiation, or targeted therapy show reprogramming of their genome to acquire resistance to the therapy. Cancer cells may mitigate the effects of radiation and chemotherapy through different mechanisms (120, 121).
Given the important roles of exosomes in cellular communication and the tumor microenvironment, many studies have indicated that exosomes are involved in anticancer therapy resistance. In one mechanism, exosomes sequester cytotoxic drugs in intracellular vesicles and subsequently negate the effects of drugs within the cells (122). Owing to the nature of exosomes as mediators of cell-cell communication in the tumor microenvironment, these exosomes play important roles in therapy resistance by transferring various contents, such as miRNAs, mRNAs, DNAs, and proteins, to induce extrinsic therapy resistance (123). Similarly, exosomes also promote therapy resistance by transferring mRNAs, miRNAs, and other components. In addition, TDEs mediate therapy resistance by different mechanism, including improved DNA repair, anti-apoptotic signaling, or delivery of transporters to treatment-sensitive cells. As mediators of mesenchymal stem cells and the EMT, exosomes also promote tumor microenvironment-associated treatment resistance (123).
Exosomes derived from drug-resistant cancer cells mediate drug resistance through direct shuttling of drugs out of the cells (124). The AKT pathway is a frequently mutated oncogenic pathway in HNSCC and functions as a key regulator of radiation resistance and a major driver of cellular movement and migration (125). Exosomes derived from irradiated HNSCC cells trigger the AKT pathway to promote migration and increase chemotaxis in recipient cancer cells (105). Radiation therapy may increase the invasive and metastatic properties of HNSCC via release of an abundance of exosomes in hypoxic cancer tissue after radiotherapy (126–128). In patients with melanoma receiving PD-1 blockade therapy, the level of circulating exosomal PD-L1 correlates with tumor burden and response to therapy (129). The PD-1/PD-L1 immune checkpoint signaling axis exhibits remarkable responses in platinum-refractory recurrent or metastatic HNSCC; PD-L1-containing TDEs, which transfer functional PD-L1 and inhibit immune responses, may be regulators and biomarkers of resistance to PD-1 blockade therapy. In addition, exosomes derived from cisplatin-resistant HNSCC cells deliver miR-21 to parental cells and induce cisplatin resistance, suggesting that these exosomes may function primarily through gene regulation (130). TDEs have been implicated in contributing to drug resistance in HNSCC (Figure 3).
Future Implications
TDEs contain numerous bioactive cellular molecules and genetic characteristics, enabling them to alter the functions of recipient cells and the tumor microenvironment. Accordingly, TDEs play important regulatory roles in cancer. Indeed, TDEs are involved in many aspects of intercellular substance transmission and signal transfer, contributing to the initiation, development, metastasis, treatment resistance, and immunosuppression of HNSCC. In HNSCC, TDEs may serve as potential clinical biomarkers of progression or responses to therapy owing to their various functional contents (proteins, genes) and elements of the parental cancer cells. Nevertheless, exosomes have not yet been applied in the treatment of HNSCC. Further studies are needed to elucidate the molecular mechanisms involved in the release of exosomes and to explore the clinical applications of these vesicles. Understanding how cancer cells utilize TDEs to promote cancer growth and progression may lead to the development of novel therapies for HNSCC. Therefore, much work is needed to establish exosome-based therapies for the treatment of HNSCC.
Statements
Author contributions
CX, FS, and NX: review concept, review design, interpretation, manuscript preparation, and manuscript review. YZ, JL, and QW: manuscript preparation and manuscript review.
Funding
This study was funded by National Health and Family Planning Commission Research Fund & Zhejiang Provincial Medical Science and Technology Plan Project (No: KWJ-ZJ-1802).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492
2.
AngKKHarrisJWheelerRWeberRRosenthalDINguyen-TanPFet al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. (2010) 363:24–35. 10.1056/NEJMoa0912217
3.
LydiattWMPatelSGO'SullivanBBrandweinMSRidgeJAMigliacciJCet al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. Cancer J Clin. (2017) 67:122–37. 10.3322/caac.21389
4.
KreimerARCliffordGMBoylePFranceschiS. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. (2005) 14:467–75. 10.1158/1055-9965.EPI-04-0551
5.
PanBTJohnstoneRM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. (1983) 33:967–78. 10.1016/0092-8674(83)90040-5
6.
KellerSRidingerJRuppAKJanssenJWAltevogtP. Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. (2011) 9:86. 10.1186/1479-5876-9-86
7.
XinTGrecoVMyungP. Hardwiring stem cell communication through tissue structure. Cell. (2016) 164:1212–25. 10.1016/j.cell.2016.02.041
8.
SteinbichlerTBDudasJRiechelmannHSkvortsovaII. The role of exosomes in cancer metastasis. Semin Cancer Biol. (2017) 44:170–81. 10.1016/j.semcancer.2017.02.006
9.
BeckerAThakurBKWeissJMKimHSPeinadoHLydenD. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. (2016) 30:836–48. 10.1016/j.ccell.2016.10.009
10.
LiuYCaoX. Organotropic metastasis: role of tumor exosomes. Cell Res. (2016) 26:149–50. 10.1038/cr.2015.153
11.
ZhangYWangXF. A niche role for cancer exosomes in metastasis. Nat Cell Biol. (2015) 17:709–11. 10.1038/ncb3181
12.
ZhangHGGrizzleWE. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol. (2014) 184:28–41. 10.1016/j.ajpath.2013.09.027
13.
WangZChenJQLiuJLTianL. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med. (2016) 14:297. 10.1186/s12967-016-1056-9
14.
RaulfNLucarelliPThavarajSBrownSVicencioJMSauterTet al. Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers. Eur J Cancer. (2018) 102:52–68. 10.1016/j.ejca.2018.07.123
15.
LiLLiCWangSWangZJiangJWangWet al. Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype. Cancer Res. (2016) 76:1770–80. 10.1158/0008-5472.CAN-15-1625
16.
WangYQinXZhuXChenWZhangJChenW. Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway. Oral Oncol. (2018) 76:34–41. 10.1016/j.oraloncology.2017.11.024
17.
LiYYTaoYWGaoSLiPZhengJMZhangSEet al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. (2018) 36:209–20. 10.1016/j.ebiom.2018.09.006
18.
XiaoMZhangJChenWChenW. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J Exp Clin Cancer Res. (2018) 37:143. 10.1186/s13046-018-0815-2
19.
MadeoMColbertPLVermeerDWLucidoCTCainJTVichayaEGet al. Cancer exosomes induce tumor innervation. Nat Commun. (2018) 9:4284. 10.1038/s41467-018-06640-0
20.
SentoSSasabeEYamamotoT. Application of a persistent heparin treatment inhibits the malignant potential of oral squamous carcinoma cells induced by tumor cell-derived exosomes. PLoS ONE. (2016) 11:e0148454. 10.1371/journal.pone.0148454
21.
AbelsERBreakefieldXO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol. (2016) 36:301–12. 10.1007/s10571-016-0366-z
22.
BlottEJGriffithsGM. Secretory lysosomes. Nat Rev Mol Cell Biol. (2002) 3:122–31. 10.1038/nrm732
23.
ColomboMMoitaCvan NielGKowalJVigneronJBenarochPet al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. (2013) 126 (Pt 24):5553–65. 10.1242/jcs.128868
24.
HenneWMBuchkovichNJEmrSD. The ESCRT pathway. Dev Cell. (2011) 21:77–91. 10.1016/j.devcel.2011.05.015
25.
KatzmannDJBabstMEmrSD. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell. (2001) 106:145–55. 10.1016/S0092-8674(01)00434-2
26.
AirolaMVHannunYA. Sphingolipid metabolism and neutral sphingomyelinases. Handb Exp Pharmacol. (2013) 215:57–76. 10.1007/978-3-7091-1368-4_3
27.
CastroBMPrietoMSilvaLC. Ceramide: a simple sphingolipid with unique biophysical properties. Prog Lipid Res. (2014) 54:53–67. 10.1016/j.plipres.2014.01.004
28.
Perez-HernandezDGutierrez-VazquezCJorgeILopez-MartinSUrsaASanchez-MadridFet al. The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. J Biol Chem. (2013) 288:11649–61. 10.1074/jbc.M112.445304
29.
ZhuHGuarigliaSYuRYLiWBranchoDPeinadoHet al. Mutation of SIMPLE in charcot-marie-tooth 1c alters production of exosomes. Mol Biol Cell. (2013) 24:1619–37, S1–3. 10.1091/mbc.e12-07-0544
30.
ColomboMRaposoGTheryC. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. (2014) 30:255–89. 10.1146/annurev-cellbio-101512-122326
31.
EkstromEJBergenfelzCvon BulowVSeriflerFCarlemalmEJonssonGet al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer. (2014) 13:88. 10.1186/1476-4598-13-88
32.
VlassovAVMagdalenoSSetterquistRConradR. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. (2012) 1820:940–8. 10.1016/j.bbagen.2012.03.017
33.
BebelmanMPSmitMJPegtelDMBaglioSR. Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. (2018) 188:1–11. 10.1016/j.pharmthera.2018.02.013
34.
WangTGilkesDMTakanoNXiangLLuoWBishopCJet al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA. (2014) 111:E3234–42. 10.1073/pnas.1410041111
35.
HoshinoDKirkbrideKCCostelloKClarkESSinhaSGrega-LarsonNet al. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep. (2013) 5:1159–68. 10.1016/j.celrep.2013.10.050
36.
VerweijFJBebelmanMPJimenezCRGarcia-VallejoJJJanssenHNeefjesJet al. Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling. J Cell Biol. (2018) 217:1129–42. 10.1083/jcb.201703206
37.
WeiYWangDJinFBianZLiLLiangHet al. Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. Nat Commun. (2017) 8:14041. 10.1038/ncomms14041
38.
WilliamsCPazosRRoyoFGonzalezERoura-FerrerMMartinezAet al. Assessing the role of surface glycans of extracellular vesicles on cellular uptake. Sci Rep. (2019) 9:11920. 10.1038/s41598-019-48499-1
39.
YellonDMDavidsonSM. Exosomes: nanoparticles involved in cardioprotection?Circ Res. (2014) 114:325–32. 10.1161/CIRCRESAHA.113.300636
40.
TheryCBoussacMVeronPRicciardi-CastagnoliPRaposoGGarinJet al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. (2001) 166:7309–18. 10.4049/jimmunol.166.12.7309
41.
ZhouWFongMYMinYSomloGLiuLPalomaresMRet al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. (2014) 25:501–15. 10.1016/j.ccr.2014.03.007
42.
MeloSASugimotoHO'ConnellJTKatoNVillanuevaAVidalAet al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. (2014) 26:707–21. 10.1016/j.ccell.2014.09.005
43.
WiluszJESunwooHSpectorDL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. (2009) 23:1494–504. 10.1101/gad.1800909
44.
ValadiHEkstromKBossiosASjostrandMLeeJJLotvallJO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. (2007) 9:654–9. 10.1038/ncb1596
45.
NonakaTWongDTW. Liquid biopsy in head and neck cancer: promises and challenges. J Dental Res. (2018) 97:701–8. 10.1177/0022034518762071
46.
HessJUngerKMaihoeferCSchuttrumpfLWintergerstLHeiderTet al. A five-microRNA signature predicts survival and disease control of patients with head and neck cancer negative for HPV infection. Clin Cancer Res. (2019) 25:1505–16. 10.1158/1078-0432.CCR-18-0776
47.
XuMJJohnsonDEGrandisJR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. (2017) 36:463–73. 10.1007/s10555-017-9687-8
48.
WhitesideTL. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagnos. (2015) 15:1293–310. 10.1586/14737159.2015.1071666
49.
WortzelIDrorSKenificCMLydenD. Exosome-mediated metastasis: communication from a distance. Dev Cell. (2019) 49:347–60. 10.1016/j.devcel.2019.04.011
50.
PrincipeSHuiABBruceJSinhaALiuFFKislingerT. Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics. (2013) 13:1608–23. 10.1002/pmic.201200533
51.
KimJWWieckowskiETaylorDDReichertTEWatkinsSWhitesideTL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. (2005) 11:1010–20.
52.
TheodorakiMNHoffmannTKJacksonEKWhitesideTL. Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. Clin Exp Immunol. (2018) 194:67–78. 10.1111/cei.13157
53.
Zlotogorski-HurvitzADayanDChaushuGSaloTVeredM. Morphological and molecular features of oral fluid-derived exosomes: oral cancer patients versus healthy individuals. J Cancer Res Clin Oncol. (2016) 142:101–10. 10.1007/s00432-015-2005-3
54.
SharmaSGillespieBMPalanisamyVGimzewskiJK. Quantitative nanostructural and single-molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes. Langmuir. (2011) 27:14394–400. 10.1021/la2038763
55.
KannanAHertweckKLPhilleyJVWellsRBDasguptaS. Genetic mutation and exosome signature of human papilloma virus associated oropharyngeal cancer. Sci Rep. (2017) 7:46102. 10.1038/srep46102
56.
Zlotogorski-HurvitzADekelBZMalonekDYahalomRVeredM. FTIR-based spectrum of salivary exosomes coupled with computational-aided discriminating analysis in the diagnosis of oral cancer. J Cancer Res Clin Oncol. (2019) 145:685–94. 10.1007/s00432-018-02827-6
57.
Momen-HeraviFBalaS. Emerging role of non-coding RNA in oral cancer. Cell Signal. (2018) 42:134–43. 10.1016/j.cellsig.2017.10.009
58.
RabinowitsGBowdenMFloresLMVerselisSVergaraVJoVYet al. Comparative analysis of microRNA expression among benign and malignant tongue tissue and plasma of patients with tongue cancer. Front Oncol. (2017) 7:191. 10.3389/fonc.2017.00191
59.
WangJZhouYLuJSunYXiaoHLiuMet al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol. (2014) 31:148. 10.1007/s12032-014-0148-8
60.
QinXGuoHWangXZhuXYanMWangXet al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. (2019) 20:12. 10.1186/s13059-018-1604-0
61.
HuangQYangJZhengJHsuehCGuoYZhouL. Characterization of selective exosomal microRNA expression profile derived from laryngeal squamous cell carcinoma detected by next generation sequencing. Oncol Rep. (2018) 40:2584–94. 10.3892/or.2018.6672
62.
GaiCCamussiFBroccolettiRGambinoACabrasMMolinaroLet al. Salivary extracellular vesicle-associated miRNAs as potential biomarkers in oral squamous cell carcinoma. BMC Cancer. (2018) 18:439. 10.1186/s12885-018-4364-z
63.
SakhaSMuramatsuTUedaKInazawaJ. Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. Sci Rep. (2016) 6:38750. 10.1038/srep38750
64.
Al-NedawiKMeehanBKerbelRSAllisonACRakJ. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA. (2009) 106:3794–9. 10.1073/pnas.0804543106
65.
HuangSHLiYZhangJRongJYeS. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Invest. (2013) 31:330–5. 10.3109/07357907.2013.789905
66.
van DommelenSMvan der MeelRvan SolingeWWCoimbraMVaderPSchiffelersRM. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells. Nanomedicine. (2016) 11:881–90. 10.2217/nnm-2015-0009
67.
LudwigSSharmaPTheodorakiMNPietrowskaMYerneniSSLangSet al. Molecular and functional profiles of exosomes from HPV(+) and HPV(-) head and neck cancer cell lines. Front Oncol. (2018) 8:445. 10.3389/fonc.2018.00445
68.
WinckFVPrado RibeiroACRamos DominguesRLingLYRiano-PachonDMRiveraCet al. Insights into immune responses in oral cancer through proteomic analysis of saliva and salivary extracellular vesicles. Sci Rep. (2015) 5:16305. 10.1038/srep16305
69.
FerrisRLBlumenscheinGJrFayetteJGuigayJColevasADLicitraLet al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. (2016) 375:1856–67. 10.1056/NEJMoa1602252
70.
ChowLQMHaddadRGuptaSMahipalAMehraRTaharaMet al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. (2016) 34:3838–45. 10.1200/JCO.2016.68.1478
71.
TheodorakiMNYerneniSSHoffmannTKGoodingWEWhitesideTL. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res. (2018) 24:896–905. 10.1158/1078-0432.CCR-17-2664
72.
Concha-BenaventeFSrivastavaRMTrivediSLeiYChandranUSeethalaRRet al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer. Cancer Res. (2016) 76:1031–43. 10.1158/0008-5472.CAN-15-2001
73.
OnoKEguchiTSogawaCCalderwoodSKFutagawaJKasaiTet al. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. J Cell Biochem. (2018) 119:7350–62. 10.1002/jcb.27039
74.
TheodorakiMNHoffmannTKWhitesideTL. Separation of plasma-derived exosomes into CD3((+)) and CD3((-)) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. Clin Exp Immunol. (2018) 192:271–83. 10.1111/cei.13113
75.
QadirFAzizMASariCPMaHDaiHWangXet al. Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation. Mol Cancer. (2018) 17:97. 10.1186/s12943-018-0846-5
76.
QuailDFJoyceJA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. (2013) 19:1423–37. 10.1038/nm.3394
77.
DayanDSaloTSaloSNybergPNurmenniemiSCosteaDEet al. Molecular crosstalk between cancer cells and tumor microenvironment components suggests potential targets for new therapeutic approaches in mobile tongue cancer. Cancer Med. (2012) 1:128–40. 10.1002/cam4.24
78.
DavisRJVan WaesCAllenCT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. (2016) 58:59–70. 10.1016/j.oraloncology.2016.05.002
79.
FilipazziPBurdekMVillaARivoltiniLHuberV. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. (2012) 22:342–9. 10.1016/j.semcancer.2012.02.005
80.
MonypennyJMilewiczHFlores-BorjaFWeitsmanGCheungAChowdhuryRet al. ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation. Cell Rep. (2018) 24:630–41. 10.1016/j.celrep.2018.06.066
81.
van der GreinSGNolte-'t HoenEN. Small Talk in the Innate immune system via RNA-containing extracellular vesicles. Front Immunol. (2014) 5:542. 10.3389/fimmu.2014.00542
82.
AucherARudnickaDDavisDM. MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation. J Immunol. (2013) 191:6250–60. 10.4049/jimmunol.1301728
83.
Vincent-SchneiderHStumptner-CuvelettePLankarDPainSRaposoGBenarochPet al. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol. (2002) 14:713–22. 10.1093/intimm/dxf048
84.
WhitesideTL. Exosomes and tumor-mediated immune suppression. J Clin Invest. (2016) 126:1216–23. 10.1172/JCI81136
85.
ShiLChenSYangLLiY. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. (2013) 6:74. 10.1186/1756-8722-6-74
86.
LudwigSFlorosTTheodorakiMNHongCSJacksonEKLangSet al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res. (2017) 23:4843–54. 10.1158/1078-0432.CCR-16-2819
87.
WolfersJLozierARaposoGRegnaultATheryCMasurierCet al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. (2001) 7:297–303. 10.1038/85438
88.
ZhangHGGrizzleWE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res. (2011) 17:959–64. 10.1158/1078-0432.CCR-10-1489
89.
MaybruckBTPfannenstielLWDiaz-MonteroMGastmanBR. Tumor-derived exosomes induce CD8(+) T cell suppressors. J Immunother Cancer. (2017) 5:65. 10.1186/s40425-017-0269-7
90.
SchulerPJSazeZHongCSMullerLGillespieDGChengDet al. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol. (2014) 177:531–43. 10.1111/cei.12354
91.
LiLCaoBLiangXLuSLuoHWangZet al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral gammadelta T cell equilibrium via tumor-derived exosomes. Oncogene. (2019) 38:2830–43. 10.1038/s41388-018-0627-z
92.
ZhouJLiMLimWQLuoZPhuaSZFHuoRet al. A transferrin-conjugated hollow nanoplatform for redox-controlled and targeted chemotherapy of tumor with reduced inflammatory reactions. Theranostics. (2018) 8:518–32. 10.7150/thno.21194
93.
WhitesideTL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin Immunol. (2018) 35:69–79. 10.1016/j.smim.2017.12.003
94.
PrincipeSMejia-GuerreroSIgnatchenkoVSinhaAIgnatchenkoAShiWet al. Proteomic analysis of cancer-associated fibroblasts reveals a paracrine role for MFAP5 in human oral tongue squamous cell carcinoma. J Proteome Res. (2018) 17:2045–59. 10.1021/acs.jproteome.7b00925
95.
VeredMLehtonenMHotakainenLPirilaETeppoSNybergPet al. Caveolin-1 accumulation in the tongue cancer tumor microenvironment is significantly associated with poor prognosis: an in-vivo and in-vitro study. BMC Cancer. (2015) 15:25. 10.1186/s12885-015-1030-6
96.
MilaneLSinghAMattheolabakisGSureshMAmijiMM. Exosome mediated communication within the tumor microenvironment. J Control Release. (2015) 219:278–94. 10.1016/j.jconrel.2015.06.029
97.
SynNWangLSethiGThieryJPGohBC. Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci. (2016) 37:606–17. 10.1016/j.tips.2016.04.006
98.
BlackwellRHForemanKEGuptaGN. The role of cancer-derived exosomes in tumorigenicity & epithelial-to-mesenchymal transition. Cancers. (2017) 9:E105. 10.3390/cancers9080105
99.
Kawakubo-YasukochiTMoriokaMHazekawaMYasukochiANishinakagawaTOnoKet al. miR-200c-3p spreads invasive capacity in human oral squamous cell carcinoma microenvironment. Mol Carcinogenesis. (2018) 57:295–302. 10.1002/mc.22744
100.
LanguinoLRSinghAPriscoMInmanGJLuginbuhlACurryJMet al. Exosome-mediated transfer from the tumor microenvironment increases TGFbeta signaling in squamous cell carcinoma. Am J Transl Res. (2016) 8:2432–7.
101.
ZhangHDengTLiuRBaiMZhouLWangXet al. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat Commun. (2017) 8:15016. 10.1038/ncomms15016
102.
HuaitongXYuanyongFYueqinTPengZWeiSKaiS. Microvesicles releasing by oral cancer cells enhance endothelial cell angiogenesis via Shh/RhoA signaling pathway. Cancer Biol Ther. (2017) 18:783–91. 10.1080/15384047.2017.1373213
103.
LudwigNYerneniSSRazzoBMWhitesideTL. Exosomes from HNSCC promote angiogenesis through reprogramming of endothelial cells. Mol Cancer Res. (2018) 16:1798–808. 10.1158/1541-7786.MCR-18-0358
104.
HsiehCHTaiSKYangMH. Snail-overexpressing cancer cells promote M2-like polarization of tumor-associated macrophages by delivering MiR-21-abundant exosomes. Neoplasia. (2018) 20:775–88. 10.1016/j.neo.2018.06.004
105.
MutschelknausLAzimzadehOHeiderTWinklerKVetterMKellRet al. Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci Rep. (2017) 7:12423. 10.1038/s41598-017-12403-6
106.
BatrakovaEVKimMS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. (2015) 219:396–405. 10.1016/j.jconrel.2015.07.030
107.
YimNRyuSWChoiKLeeKRLeeSChoiHet al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun. (2016) 7:12277. 10.1038/ncomms12277
108.
SynNLWangLChowEKLimCTGohBC. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. (2017) 35:665–76. 10.1016/j.tibtech.2017.03.004
109.
WuKXingFWuSYWatabeK. Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside. Biochim Biophys Acta Rev Cancer. (2017) 1868:538–63. 10.1016/j.bbcan.2017.10.001
110.
LiLPiontekKIshidaMFaustherMDranoffJAFuRet al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. (2017) 65:501–14. 10.1002/hep.28735
111.
KooijmansSAAlezaCGRofflerSRvan SolingeWWVaderPSchiffelersRM. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles. (2016) 5:31053. 10.3402/jev.v5.31053
112.
YangTMartinPFogartyBBrownASchurmanKPhippsRet al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. (2015) 32:2003–14. 10.1007/s11095-014-1593-y
113.
WangCChenLHuangYLiKJinyeAFanTet al. Exosome-delivered TRPP2 siRNA inhibits the epithelial-mesenchymal transition of FaDu cells. Oncol Lett. (2019) 17:1953–61. 10.3892/ol.2018.9752
114.
MurphyDACourtneidgeSA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. (2011) 12:413–26. 10.1038/nrm3141
115.
SharmaAKhatunZShirasA. Tumor exosomes: cellular postmen of cancer diagnosis and personalized therapy. Nanomedicine. (2016) 11:421–37. 10.2217/nnm.15.210
116.
HaoSBaiOLiFYuanJLaferteSXiangJ. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology. (2007) 120:90–102. 10.1111/j.1365-2567.2006.02483.x
117.
HoneggerALeitzJBulkescherJHoppe-SeylerKHoppe-SeylerF. Silencing of human papillomavirus (HPV) E6/E7 oncogene expression affects both the contents and the amounts of extracellular microvesicles released from HPV-positive cancer cells. Int J Cancer. (2013) 133:1631–42. 10.1002/ijc.28164
118.
Di BonitoPAccardiLGalatiLFerrantelliFFedericoM. Anti-cancer vaccine for HPV-associated neoplasms: focus on a therapeutic HPV vaccine based on a novel tumor antigen delivery method using endogenously engineered exosomes. Cancers. (2019) 11:E138. 10.3390/cancers11020138
119.
CramerJDBurtnessBLeQTFerrisRL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. (2019). 10.1038/s41571-019-0227-z. [Epub ahead of print].
120.
MeadsMBGatenbyRADaltonWS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. (2009) 9:665–74. 10.1038/nrc2714
121.
MoitraKLouHDeanM. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. (2011) 89:491–502. 10.1038/clpt.2011.14
122.
SheddenKXieXTChandaroyPChangYTRosaniaGR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. (2003) 63:4331–7.
123.
SteinbichlerTBDudasJSkvortsovSGanswindtURiechelmannHSkvortsovaII. Therapy resistance mediated by exosomes. Mol Cancer. (2019) 18:58. 10.1186/s12943-019-0970-x
124.
NameeNMO'DriscollL. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer. (2018) 1870:123–36. 10.1016/j.bbcan.2018.07.003
125.
BussinkJvan der KogelAJKaandersJH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. (2008) 9:288–96. 10.1016/S1470-2045(08)70073-1
126.
PickhardACMargrafJKnopfAStarkTPiontekGBeckCet al. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer. (2011) 11:388. 10.1186/1471-2407-11-388
127.
BeckCPiontekGHaugABasMKnopfAStarkTet al. The kallikrein-kinin-system in head and neck squamous cell carcinoma (HNSCC) and its role in tumour survival, invasion, migration and response to radiotherapy. Oral Oncol. (2012) 48:1208–19. 10.1016/j.oraloncology.2012.06.001
128.
MutschelknausLPetersCWinklerKYentrapalliRHeiderTAtkinsonMJet al. Exosomes derived from squamous head and neck cancer promote cell survival after ionizing radiation. PLoS ONE. (2016) 11:e0152213. 10.1371/journal.pone.0152213
129.
ChenGHuangACZhangWZhangGWuMXuWet al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. (2018) 560:382–6. 10.1038/s41586-018-0392-8
130.
LiuTChenGSunDLeiMLiYZhouCet al. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma. Acta Biochim Biophys Sin. (2017) 49:808–16. 10.1093/abbs/gmx078
Summary
Keywords
exosomes, head and neck squamous cell carcinoma, tumor microenvironment, biomarkers, therapy resistance
Citation
Xiao C, Song F, Zheng YL, Lv J, Wang QF and Xu N (2019) Exosomes in Head and Neck Squamous Cell Carcinoma. Front. Oncol. 9:894. doi: 10.3389/fonc.2019.00894
Received
25 May 2019
Accepted
27 August 2019
Published
18 September 2019
Volume
9 - 2019
Edited by
Cheng-Chia Yu, Chung Shan Medical University, Taiwan
Reviewed by
Augusto Schneider, Universidade Federal de Pelotas, Brazil; Yin-Hwa Eva Shih, Asia University, Taiwan
Updates
Copyright
© 2019 Xiao, Song, Zheng, Lv, Wang and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nong Xu nongxu@zju.edu.cn
This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.